HepaSphere载药微球栓塞治疗不可切除肝癌15例  

Interventional chemoembolization with hepasphere- loaded microspheres for the treatment of unresectable hepatocellular carcinoma: preliminary results in 15 cases

作　　者：周官辉[1] 孙军辉[1] 张岳林[1] 聂春晖[1] 周坦洋[1] 朱统寅[1] 王宝泉[1] 陈圣群[1] 陈黎明[1] 王伟林[1] 郑树森[1] 

机构地区：[1]浙江大学医学院附属第一医院肝胆胰介入中心,杭州31003

出　　处：《介入放射学杂志》2015年第10期869-872,共4页Journal of Interventional Radiology

基　　金：国家传染病重大专项项目(2012ZXl0002-017);国家自然科学基金(81371658);国家自然科学基金(81172315);国家自然科学基金青年基金(30901446);浙江省医药卫生科研项目(2013KYB097)

摘　　要：目的观察新型载药栓塞微球（HepaSphere）治疗不可切除肝癌的安全性及近期临床疗效。方法15例不可切除肝癌患者在经导管动脉化疗栓塞术（TACE）中使HepaSphere微球栓塞．对患者临床资料、影像随访资料、介入治疗的并发症和预后等情况进行总结和分析。采用改良实体瘤疗效评价标准（mRECIST），术后每月随访1次。15例患者共行23次TACE。结果15例患者随访6。15个月．中位随访时间为10个月，根据mRECIST标准，3个月疾病缓解率（CR＋PR）为73．3％，疾病控制率（CR＋PR＋SD）为93．3％，6个月疾病缓解率（CR＋PR）为73_3％，疾病控制率（CR＋PR＋SD）为86．7％。所有患者均未出现胆汁漏并发感染、肝脓肿、腹腔出血、肿瘤破裂出血及消化道出血等严重并发症。结论应用新型HepaSphere微球栓寨治疗不可切除肝痛的近期临床疗效及安伞忡均较好．远期妁果仍需扩大样本讲一击讽察．Objective To evaluate the safety and clinical short-term efficacy of interventional emboliz- ation with hepasphere-loaded microspheres in treating inoperable hepatoeellular carcinomas. Methods A total of 15 patients with unresectable hepatocellular carcinoma underwent transcatheter arterial ehemoembolization （TACE） using hepasphere-loaded microspheres as embolic agent. The clinical data, imaging follow-up materials, complications of interventional treatment, prognosis, etc. were summarized and analyzed. The results were evaluated with modified response evaluation criteria in solid tumors （mRECIST） ; monthly follow- up was made for all patients. A total of 23 TACE procedures were performed in 15 patients. Results The following-up period ranged from 6 months to 15 months, the median follow-up time being 10 months. According to mRECIST, the 3-month objective response rate （CR＋PR） was 73.3% and disease control rate （CR＋PR＋SD） was 93.3%; the 6-month objective response rate （CR＋PR） was 73.3% and the disease control rate （CR＋PR＋SD） was 86.7%. No severe complications, such as bile leak complicated by infection, liver abscess, abdominal hemorrhage, bleeding due to tumor rupture, gastrointestinal bleeding, etc. occurred in all patients. Conclusion In treating unresectable hepatocellular carcinomas, TACE using newly- developed hepasphere microspheres carries satisfactory clinical short-term efficacy and safety, although the log-term results need to be further investigated with larger sample trial.

关 键 词：TACE 肝癌 HepaSphere微球 载药微球 

分 类 号：R735.7[医药卫生—肿瘤]